Detection of species of Exophiala and Scedosporium in the respiratory tracts of cystic fibrosis (CF) patients remains controversial because of highly variable results. The results of our study suggested a significantly higher prevalence and more complex colonization than previously estimated. Approximately 17% (27/162) of clinical sputum samples were found to be positive for Exophiala dermatitidis and 30% (49/162) were positive for Scedosporium apiospermum / S. boydii species complex determined by reverse line blot (RLB) hybridization. In contrast, only 14.2% (23/162) and 1.2% (2/162) of clinical sputa were positive for E. dermatitidis and S. apiospermum / S. boydii species complex when tested by culture, respectively. Molecular detection methods, such as loop-mediated isothermal amplification (LAMP) or reverse line blot (RLB) hybridization, have the potential to become powerful alternatives to selective culture, providing a more realistic understanding on the prevalence of E. dermatitidis and S. apiospermum / S. boydii species complex in the respiratory tract of CF patients.
Introduction
Affecting over 70,000 individuals worldwide, cystic fibrosis (CF) is the most common genetically inherited disease among Caucasian populations. 1 CF is caused by mutations in the CF transmembrane conductance regulator (CFTR) protein, which leads to the production of thick and sticky bronchial mucus that may facilitate microbial accumulation and colonization. 2, 3 In addition to bacteria such as Staphylococcus aureus and Pseudomonas aeruginosa, several fungi colonize the respiratory tracts of CF patients, 3, 4 though their prevalence and pathogenicity remain controversial. 5, 6 Aspergillus fumigatus is the filamentous fungus most commonly isolated from CF patients and is capable of precipitating a chronic allergic inflammatory response or invasive infection after lung transplantation. 4 However, the fungal biota colonizing the lungs of CF patients are more complex and include various non-Aspergillus filamentous fungi such as Scedosporium apiospermum [7] [8] [9] and Exophiala dermatitidis. 4, [10] [11] [12] In the genus Scedosporium, S. apiospermum, and S. boydii have recently been aggregated as the 'S. apiospermum complex' because of their genetic similarity and the lack of clinical differences observed between sibling species. 13, 14 The black yeast E. dermatitidis is another filamentous fungus regularly involved in colonizing the respiratory tract of CF patients. [7] [8] [9] [10] [11] [12] Persistent colonization and repeated infection with E. dermatitidis or S. apiospermum / S. boydii may occur in CF patients over decades. [10] [11] [12] Scedosporium species are resistant to many antifungal agents including amphotericin B. 15 In addition to Aspergillus and Candida, patients with CF were observed to be colonized by E. dermatitidis or Scedosporium; however, this may be an artifact because published studies that detected them in combination are scant. In addition, culture only has a limited sensitivity, these species usually remain undetected because they are easily outcompeted by Aspergillus and Candida species. 15, 17 Possible correlations with underlying diseases remain uncertain because of limited amount of data available. An exceptionally high recovery rate of approximately 20% of E. dermatitidis was recently reported by incubating sputa on erythritol-chloramphenicol agar (ECA) medium from Sweden, but conventional culture-based diagnosis strategies are hampered by the mucoid consistency of CF sputum or bronchoalveolar lavage (BAL) specimens. 18 Thus, frequencies of accompanying fungi may be underestimated, 12, 18 though recent applications of semi-selective media, which inhibit rapidly growing Aspergillus and Candida, enable fungi with delayed growth to be revealed. 19, 20 Detection by culture still requires viable cells in the samples and highly skilled laboratory technicians for successful cultivation. Molecular techniques have improved detection and thereby our understanding of fungal colonization of the respiratory tracts of CF patients. 21, 22 Among these methods, loop-mediated isothermal amplification (LAMP) 21 and reverse line blot (RLB) hybridization 7, 21 have shown added value to elucidation of the epidemiology of less common colonizers in the CF patient population. 7, 21, 22 
Methods

Clinical specimens
Between September and December 2012, a total of 162 sputum specimens from 103 CF patients were collected by the Department of Clinical Microbiology, Sahlgrenska University Hospital, Sweden. Each sample was divided into two portions: one part for the isolation of conventional or semiselective culture, the other part for molecular detection by PCR-RLB and LAMP assays. 
Molecular detection
Genomic DNA from reference strains was extracted using cetyltrimethylammonium bromide (CTAB) as described previously. 14 To extract fungal DNA directly from clinical sputum, a High Pure PCR Template Preparation Kit (Roche Inc., Mannheim, Germany) was used according to healthy donor for sensitivity testing in spiked specimens and as positive controls, with 10 times dilution of fungal cells.
PCR-RLB
A primer set for E. dermatitidis targeting the BT2 region of the β-tubulin gene was designed (Table 2) . Additionally, the primers developed by Lu et al. were used for Scedosporium. 7, 21 Two species-specific probes and a species complex specific probe PE P specific for Exophiala species were labeled with C6-amino linker at the 5 end. All primers and probes were BLAST searched against nucleotide databases available at GenBank and the CBS in-home database, to verify specificity. PCR amplification of BT2 was performed consisting of 1 × GoTaq Green Master Mix (Promega, Fitchburg, WI, USA), 400 nmol of primers and 2 μl template DNA (100 ng/μl) to 94
• C for 5 min, followed by 35 cycles of 94
• C for 45 s, 56
• C for 45 s, 72
• C for 90 s and post-elongation at 72
• C for 7 min. Sensitivity tests were repeated twice using 10-fold serial dilutions (ranging from 200 ng/ml to 2 pg/ml) of template DNA extracted from reference strains and spiked sputum specimens (ranging from 4800 fungal cells/ml to 4.8 fungal cells/ml).
LAMP
Assays for detection of Scedosporium species were performed as previously described. • C for 2 min to terminate the reaction. Similarly, the sensitivity tests were repeated twice using template DNA extracted from reference strains and spiked sputum specimens, respectively.
Statistical analysis
The statistical package for SAS version 9.3 (SAS Institute, Cary, NC, USA) was used to analyze the data. The obtained data were evaluated by percentage ratios. Comparison of percentage ratios yielded by molecular assays was accomplished using the χ 2 test. A P value of less than .05 was considered to be statistically significant. 
Results
A total of 162 clinical sputum samples were verified for growth of E. dermatitidis and Scedosporium species. E. dermatitidis was detected in 23 sputum samples (14.2%) using selective ECA culture, while S. apiospermum / S. boydii was detected in two samples (1.2%) using nonselective routine media.
Detection by PCR-RLB
The specificity and sensitivity of the PCR-RLB assay for S. apiospermum and S. boydii has previously been reported to be 100% and approximately 5.0 × 10 3 copies of genomic DNA for specificity and sensitivity. 21 Genomic DNA from 46 reference and clinical strains covering each of the main genotypes of E. dermatitidis were analyzed to determine the specificity of our newly-designed PCR-RLB assay for E. dermatitidis (Table 1) . No cross-reaction was observed, including DNA of a sibling species, E. phaeomuriformis, CBS 109146. Thus, specificity of the PCR-RLB assay was 100% in our study. The detection limit of PCR-RLB for genomic DNA of E. dermatitidis was approximately 1.1 × 10 3 genomic DNA copies (20 pg) per run. Sensitivity of the PCR-RLB assay was determined using spiked samples, in which concentrations above 4.8 × 10 3 E. dermatitidis spores/ml were positive. The PCR-RLB assay detected E. dermatitidis in approximately 17% of clinical samples (Fig. 1) . Among the 23 E. dermatitidis culture -positive samples, 21 samples were positive by the PCR-RLB assay. The PCR-RLB assay yielded approximately 30% positive S. apiospermum / S. boydii, of which 4% were S. apiospermum and 26% were S. boydii, respectively (Fig. 1) . Only one of the two Scedosporium culture-positive samples was confirmed to be positive by PCR-RLB assay.
Detection by LAMP
The specificity and sensitivity of the LAMP assay for S. apiospermum / S. boydii were previously shown to be 100% and approximately 5.0 × 10 2 copies of genomic DNA, respectively. 21 In this study, no cross-reaction with any of the tested Exophiala species was observed after 90 minutes of the LAMP reaction ( Table 1 ). The sensitivity of the LAMP assay was then further evaluated with spiked sputum samples, in which concentrations above 4.8 × 10 2 E.
dermatitidis cells/ml were positive. A total of 162 sputum samples, including two Scedosporium-culture positive samples and 23 E. dermatitidis-culture positive samples, were analyzed by our LAMP assay. LAMP assay of the DNA extracted from sputa yielded 32% of positive S. apiospermum / S. boydii samples. Both Scedosporium culture-positive samples were confirmed to be positive by LAMP. Additionally, the LAMP assay detected E. dermatitidis in 30% of clinical samples, and 49 samples were E. dermatitidis positive by LAMP, including the E. dermatitidis-culture positive samples.
Comparison of results yielded from culture, PCR-RLB, and LAMP
Of the 162 sputum samples from CF patients, 12 clinical samples were positive by both PCR-RLB and LAMP, whereas five LAMP-negative samples were PCR-RLB positive, 36 PCR-RLB-negative samples were positive with LAMP, and 109 of the total samples were negative by both PCR-RLB and LAMP. For E. dermatitidis, 14% of the samples were positive by culture, 17% by PCR-RLB, 30% by LAMP and 14% were positive by both PCR-RLB and LAMP. For Scedosporium, LAMP had a higher detection rate (27%) than PCR-RLB (P < .0001). Similarly, the LAMP assay also provided a higher detection rate (30%) for E. dermatitidis (P = .0039).
Discussion
Previous studies revealed a highly variable prevalence of Exophiala and Scedosporium species in the respiratory tracts of CF patients (Table 3) . 8, 12, 16, 17, [25] [26] [27] [28] [29] [30] [31] Lack of standardization of the procedures for detection on filamentous fungi in sputum samples from CF patients may be a possible cause for the variable reported data. 31 Moreover, routine processing procedures for isolating filamentous fungi from respiratory sputum samples may underestimate fungal prevalence. 18 Notably, LAMP technology can rapidly and accurately amplify genomic DNA in an isothermal step from partially processed and/or nonprocessed samples in approximately 1 hour without the need for sophisticated equipment and the products can be assessed by the naked eye. 32 The PCR-RLB assay has been used to detect Scedosporium species in the respiratory samples of CF patients. 7 Thus, E. dermatitidis-specific and Scedosporiumspecific molecular assays, PCR-RLB and LAMP, and culture assays were used to detect the prevalence of E. dermatitidis and Scedosporium species in 162 clinical sputa in a double blind experiment. We noticed that only two samples were positive for S. apiospermum / S. boydii and 23 samples were positive for E. dermatitidis upon culture assay in our study. This may due to cultivation of Exophiala by selective medium, and Scedosporium culture was nonselective. Some filamentous fungi such as A. fumigatus can overlap other fungi such as Scedosporium species on non-selective medium because they grow faster than other non-Aspergillus fungi that colonize the respiratory tract of CF patients. 4 Generally, our results are similar to the recovery rates reported using comparable media for Scedosporium species and E. dermatitidis. [10] [11] [12] 33, 34 In contrast, positive recovery rates
for Scedosporium tend to increase at approximately 15% when the sputum samples processed by benomyl-based media. 33 In addition to A. fumigatus, E. dermatitidis and species of the S. apiospermum complex are the most frequent molds recovered from respiratory secretions of CF patients, but their recovery rates vary greatly. 18, 34, 35 With its ability to grow at 37
• C, E. dermatitidis has a worldwide distribution in hot environments, not only in CF respiratory tracts 10, 26, 36, 37 but also warm indoor environments such as steambaths 38 and dishwashers. 39 Although the significance of E. dermatitidis in causing disease in patients with CF remains unclear, this fungus is known to cause severe invasive fungal infections. 40 With selective ECA medium, the prevalence of E. dermatitidis ranges from 5% in Germany to 19% in Sweden. 11, 12, 18 Published recovery rates in Sweden were exceptionally high, around 17-19% by selective culture. 12, 37 Our data, which were also from Sweden, showed a high positive rate of 14%, confirming that this detection rate is rather consistent. PCR-RLB and LAMP assays yielded 15 and 30% of E. dermatitis detection, respectively, which was significantly higher than culture. The prevalence in Sweden is 2 to almost 20 times higher than in European countries, which is possibly because of differences in indoor conditions. For a better understanding of E. dermatitidis prevalence among CF patients, further multi-center epidemiological studies are needed. Regarding the positive rate for Scedosporium species, the results of our molecular assays showed that approximately 10.5% of the CF airway samples were positive for the S. apiospermum complex using the PCR-RLB assay, and the positive rate yielded by the LAMP assay was approximately 31.5%. This positive rate for S. apiospermum / S. boydii was lower than the maximum reported rate of 61.5% that was obtained using PCR-RLB. 7 The high detection rate yielded by LAMP is likely closest to actual value, and LAMP technology would be the most efficient for amplification of target DNA from partially processed and/or non-processed CF specimens. 32 The selective ECA medium yielded a comparatively high positive recovery rate of E. dermatitidis, and this figure might be tripled to approach the real prevalence generated by molecular methods. However, LAMP may have a higher risk of false positive results than PCR-RLB, which might be caused by pre-PCR contamination of samples, as the method is highly sensitive. Careful precautions to prevent cross-contamination need to be taken during sample collection, and the methods should be executed using separated rooms and filtered tips. In general, analysis of larger numbers of samples is required to determine their prevalence in clinical samples, and the method should be repeated several times to enable for reliable determination of the presence in a single patient. The recent application of next-generation sequencing (NGS) technology has allowed us to conduct meta-genomic studies, 41 which may provide more comprehensive insight into chronic fungi colonization in airways of CF patients. Finally, we noticed two samples with positive culture results for E. dermatitidis were negative upon both PCR-RLB and LAMP assays. The quality of the fungi DNA extracted from respiratory sputum samples is likely poor, and sputa from CF patients might contain PCR inhibiting substances, both of which could influence the performance of the molecular assays. In summary, current data on the prevalence of Exophiala and Scedosporium in the respiratory tract of CF patients remains variable and controversial. The results of our comparative detection study suggested a significantly higher prevalence and more complex colonization than previously estimated. Molecular detection methods such as the LAMP or NGS technology have the potential to become powerful tools that can be used in place of selective culture for to provide a more realistic description of the prevalence of Exophiala and Scedosporium in the respiratory tracts of CF patients, upon the improvement of the protocols for the extraction of filamentous fungi DNA from clinical specimens.
